Influenza

Pharmaceutical company receives grant to test influenza drug candidate

Published in Hepatitis Weekly, September 5th, 2005

NexBio, Inc., announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. National Institutes of Health (NIH), has awarded the company a $6 million phase II SBIR grant to further test the company's lead drug candidate, Fludase (DAS181), for the prevention and treatment of influenza.

NexBio recently completed a preinvestigational new drug application (NDA) meeting with the U.S. Food and Drug Administration (FDA) and will submit an investigational new drug application (IND) to FDA and initiate human trials on Fludase shortly thereafter.

Fludase represents a first-in-class approach to fight influenza....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2005-09-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry